Approval · Notice of Compliance 15567 · 2014
MINT-PREGABALIN: Notice of Compliance 15567
Issued May 2, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15567
- Date
- May 2, 2014
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Analgesic agent
- Canadian reference product
- LYRICA (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-PREGABALIN | 02423804 | Marketed |
| MINT-PREGABALIN | 02423812 | Marketed |
| MINT-PREGABALIN | 02424185 | Marketed |
| MINT-PREGABALIN | 02424193 | Approved |
| MINT-PREGABALIN | 02424207 | Marketed |
| MINT-PREGABALIN | 02424215 | Approved |
| MINT-PREGABALIN | 02424223 | Approved |
| MINT-PREGABALIN | 02424231 | Approved |
Medicinal ingredients
- PREGABALIN 25 MG per CAP
- PREGABALIN 50 MG per CAP
- PREGABALIN 75 MG per CAP
- PREGABALIN 100 MG per CAP
- PREGABALIN 150 MG per CAP
- PREGABALIN 200 MG per CAP
- PREGABALIN 225 MG per CAP
- PREGABALIN 300 MG per CAP